Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial summarizes recent evidence on residual inflammatory risk post-PCI, preventive PCI for vulnerable plaques in diabetics, and OCT-guided PCI for calcified lesions.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. This Issue opens with a President’s Page entitled ‘CardioMetabolic Medicine: the revival of the cardiovascular generalist?’ by Thomas F. Lüscher.1 The President notes that cardiometabolic medicine is centre stage as it integrates organ dysfunction in the pancreas, kidney, liver, and the heart induced by the pandemic of obesity leading to a high risk of heart failure with preserved or reduced ejection fraction, myocardial infarction, stroke, and premature death. This novel specialty involves generalized training across several specialties to provide optimal care of the increasing number of patients with that condition. The issue continues with a focus on interventional cardiology and cardiac and vascular surgery. In a contribution entitled ‘Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence’, Colin Baigent and Rafael Sádaba from the University of Oxford in the UK and the University of Navarra in Pamplona, Spain, that refers to the ‘2022 joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG’ by Robert A. Byrne et al. from the RCSI University of Medicine and Health Sciences in Dublin, Ireland.2,3 Aortic stenosis (AS) has become a major health burden, with a reported prevalence of 2%–6% in the population older than 65 years. The outcome of symptomatic severe AS was already recognized to be dismal decades ago, while successful surgical aortic valve replacement (SAVR) and later transcatheter aortic valve implantation (TAVI) have been demonstrated to provide a dramatic outcome improvement for this population.4–12 In a Great Debate article entitled ‘Great debate: Transcatheter aortic valve implantation should also be performed in non-surgical centres’, Helmut Baumgartner from the University Hospital in Muenster, Germany13 note that the requirement for cardiac surgery on site for TAVI has been challenged for many years, but studies reporting safety and efficacy for non-surgical sites were limited primarily by the observational design of the studies. As a matter of fact, the rapidly increasing referrals for TAVI which now exceed by far the number of surgical procedures cannot be accomplished by the available resources, leading to unacceptably long waiting times with their markedly negative impact on outcomes. This raises the question of whether TAVI should also be performed in non-surgical centres to increase its availability. Thus, it is timely to discuss the pros and contras of performing TAVI also in non-surgical centres in this Great Debate. Structured Graphical Abstract16 Elevated LDL-cholesterol levels and inflammation, as assessed by high-sensitivity C-reactive protein (hsCRP), correlate with cardiovascular risk.14,15 However, data on the relative impact of residual LDL-cholesterol and inflammatory risk among statin-treated patients undergoing percutaneous coronary intervention (PCI) are lacking. In a Clinical Research article entitled ‘Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention’, Benjamin Bay from the Icahn School of Medicine at Mount Sinai in New York, NY, USA, and colleagues aim to investigate the impact of residual cholesterol/inflammatory risk in patients on statin therapy undergoing PCI.16 From 2012 to 2022, patients at a tertiary centre undergoing PCI were analysed. Patients were stratified according to LDL-cholesterol (≥70 vs. < 70 mg/dL) and hsCRP (≥2 vs <2 mg/L) levels in four groups: no residual cholesterol or inflammatory risk; residual cholesterol risk; residual inflammatory risk; and combined residual cholesterol and inflammatory risk. Patients presenting with acute myocardial infarction, cancer, no statin treatment at admission, or hsCRP >10 mg/L were excluded. The primary endpoint was major adverse cardiovascular events (MACE), defined as the composite of all-cause mortality, spontaneous myocardial infarction, and stroke 1 year after the index PCI. A total of ∼15 500 patients were included. After 1 year follow-up, individuals with isolated residual inflammatory risk had the highest MACE rate (5.1%), followed by patients with combined cholesterol and inflammatory risk, no residual risk, and isolated residual cholesterol risk. After multivariable Cox regression analysis, patients with residual inflammatory risk had a 1.8-fold higher risk for MACE (P < .001) compared with those with no residual cholesterol or inflammatory risk. Of note, no independent association of isolated residual cholesterol risk (P = .920) with MACE was noted. The authors conclude that among statin-treated patients undergoing PCI, residual inflammation, but not cholesterol risk, is associated with an increased risk of MACE during follow-up. The manuscript is accompanied by an Editorial by Anders B. Wulff and Børge G. Nordestgaard from Herlev and Gentofte Hospital in Denmark.17 The authors note that Bay et al. provide an important contribution to the scientific field, cementing the fact that elevated LDL-cholesterol in patients already treated with LDL-cholesterol-lowering drugs is a poor marker for future risk of atherosclerotic cardiovascular disease (ASCVD). At the same time, they show a strong association of elevated hsCRP with future MACE risk, and suggest that this residual risk potentially could be addressed using anti-inflammatory drugs. They suggest elevated remnant cholesterol and elevated lipoprotein(a) as additional causes of residual risk that should not be ignored, especially as high concentrations of remnant cholesterol and lipoprotein(a) are likely causes of both inflammation and residual risk in those treated with statins and other LDL-cholesterol-lowering therapies. That said, reducing LDL-cholesterol to levels recommended in guidelines remains an important target. Finally, while low-grade inflammation, elevated remnant cholesterol, and elevated lipoprotein(a) are emerging factors, the clinical benefit of targeting them still requires definitive trials. The efficacy and safety of preventive PCI for treating vulnerable plaques in diabetic patients remain unclear. In a Clinical Research article entitled ‘Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial’, Min Chul Kim from Chonnam National University Hospital in Gwangju, South Korea, and colleagues analysed data from the Preventive Coronary Intervention on Stenosis with Functionally Insignificant Vulnerable Plaque (PREVENT) trial, a randomized clinical trial that compared preventive PCI plus optimal medical therapy (OMT) vs. OMT alone in patients with non-flow-limiting (fractional flow reserve [FFR] > 0.800) vulnerable plaques.18 Randomization was stratified by diabetes status. The primary endpoint was a composite of cardiac death, target-vessel myocardial infarction, ischaemia-driven target-vessel revascularization, or hospitalization for unstable or progressive angina at 2 years. Among 1606 randomized patients, 30% had diabetes. Diabetic patients underwent PCI for non-target lesions before randomization more frequently than non-diabetics (P = .009). There were no significant differences in the incidence of the primary endpoint between diabetic and non-diabetic patients (1.8% vs. 1.9%; P = .956). The primary endpoint at 2 years was less frequent with preventive PCI compared with OMT alone in both diabetic (0% vs. 3.7%; P = .004) and non-diabetic patients (0.5% vs. 3.2%; P = .004), without a significant interaction between diabetic status and randomized strategy. The authors conclude that the risk of adverse clinical events is similar between diabetic and non-diabetic patients with non-flow-limiting vulnerable coronary plaques. However, preventive PCI is associated with a lower incidence of the primary endpoint at 2 years, regardless of diabetes status. The manuscript is accompanied by an Editorial by Diana A. Gorog from Imperial College of London, UK.19 The author concludes that the new subgroup analysis of patients with diabetes in the PREVENT trial furthers our understanding of residual risk. It shows that prophylactic PCI in patients with non-flow-limiting vulnerable plaques in diabetic patients reduces the risk of subsequent PCI to the same lesion, but appears not to reduce the risk of target vessel infarction. This indicates that vulnerable plaques may be just one marker of a vulnerable patient, but not the only determinant of risk. Perhaps we need to find better ways of identifying the vulnerable patient, rather than focusing solely on vulnerable plaques. Structured Graphical Abstract24 Vascular calcifications have a complex pathophysiology.20–23 Despite advancements in technology, coronary artery calcification remains a significant challenge in PCI. PCI of calcified coronary lesions is associated with an increased risk of suboptimal stent implantation, procedural complications, and long-term adverse events. In a Clinical Research article entitled ‘Optical coherence tomography- vs. angiography-guided coronary stent implantation in calcified lesions: the ILUMIEN IV trial’, Ziad A Ali from St. Francis Hospital and Heart Center in Roslyn, NY, USA, and colleagues aim to compare optical coherence tomography (OCT)-guided PCI with angiography-guided PCI in the subgroup of patients with angiographically calcified coronary lesions in the ILUMIEN IV: OPTIMAL PCI trial.24 The large-scale, randomized ILUMIEN IV trial assessed whether procedural guidance with OCT during PCI of angiographically calcified lesions improves outcomes. Patients with a single PCI target lesion were included in the present analysis. The presence of no, mild, moderate, or severe lesion calcification was determined by an angiographic core laboratory. The primary imaging endpoint was the post-PCI minimal stent area (MSA) assessed by OCT. The primary clinical endpoint was 2 year target-vessel failure (TVF), a composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischaemia-driven target-vessel revascularization. In the overall population (n = 2114), there was a significant interaction between the effect of randomization to OCT guidance vs. angiography guidance in lesions with moderate/severe calcification vs. no/mild calcification on the 2 year rate of TVF (Pinteraction = .01). The post-PCI minimal stent area in moderately and severely calcified lesions was larger with OCT guidance compared with angiography guidance (P = .03). In the moderate/severe calcified lesion cohort, TVF within 2 years occurred in 35 patients with OCT guidance and in 51 patients with angiography guidance (6.8% vs. 9.7%; adjusted hazard ratio [aHR] 0.62), whereas there was no significant difference in TVF in the no/mild calcified lesion cohort (Pinteraction = .01). In moderately/severely calcified lesions, OCT-guided PCI also reduced the 2 year rates of TV-MI (P = .01), and stent thrombosis (P = .04) compared with angiography-guided PCI. The authors conclude that in the ILUMIEN IV trial, OCT-guided PCI in patients with angiographically determined moderately or severely calcified lesions reduces the 2 year rate of TVF compared with angiography-guided PCI, an effect that is not seen in patients with lesions with no or mild angiographic calcium. The manuscript is accompanied by an Editorial by Marta Belmonte and Emanuele Barbato from Sant’Andrea University Hosptial in Rome, Italy.25 The authors note that in an effort to simplify and optimize percutaneous management strategies for heavily calcified coronary stenoses, the 2023 European Association of Percutaneous Cardiovascular Interventions Clinical Consensus Statement has emphasized the critical role of intravascular imaging—either OCT or intravascular ultrasound—in guiding the operator’s decision-making regarding advanced plaque modification tools and techniques, tailoring their use according to calcification severity. Imaging-guided algorithmic interventional approaches for heavily calcified lesions are currently being tested in randomized clinical trials and, if proven beneficial, they would support the systematic adoption of intravascular imaging in this challenging lesion subset. The path to achieving optimal PCI outcomes in heavily calcified stenoses is becoming clearer. As a community, we must now focus on validating protocols and algorithms that can enhance patient outcomes in a safe and reproducible manner. Physiological flow assessment of coronary stenoses, such as FFR, is routinely used to guide PCI, but it has not been equally recognized to guide coronary artery bypass grafting (CABG). In a Clinical Research article entitled ‘Coronary artery bypass grafting with or without pre-operative physiological stenosis assessment: a SWEDEHEART study’, Emma C. Hansson from Sahlgrenska University Hospital in Gothenburg, Sweden, and colleagues aim to describe the use of flow assessment before CABG over time in a large nationwide cohort study and compare short- and mid-term outcomes after CABG between patients with and without flow assessment prior to surgery.26 All patients with first-time isolated CABG in Sweden from 2013 to 2020 were identified in the SWEDEHEART registry (n = 18 211), which also provided information on flow assessment. Median follow-up was 3.6 years (range 0–7.5). Incidence of all-cause mortality, stroke, new myocardial infarction, new coronary angiography, and new revascularization was compared using adjusted Cox regression models. The proportional hazard assumption was violated for new angiography and revascularization. Hence, follow-up was divided into 0–2 and >2 years. Overall, 16% of patients had flow assessment before surgery, increasing from 7.1% in 2013 to 21% in 2020. Patients with flow assessment were younger, had a lower EuroSCORE II, and received fewer distal anastomoses (P < .001). There were no associations between flow assessment and mortality, post-discharge myocardial infarction, or stroke. New angiography and new revascularization were not significantly different at 0–2 years, but pre-operative flow assessment was associated with a higher risk for new angiography (aHR 1.32, P = .008) and new revascularization (aHR 1.55, P = .002) > 2 years after CABG. The authors conclude that pre-operative flow assessment is not associated with improved clinical outcomes but with a higher risk for new angiography and new revascularization >2 years after CABG.. The manuscript is accompanied by an Editorial by Philippe Kolh, Vincent Tchana-Sato, and Thomas A. Schwann from the University of Liège in Belgium, and Oakland University in Royal Oak, MI, USA.27 The authors conclude that the current study adds further weight to the perspective that the efficacy of flow assessment of lesions treated by PCI cannot and should not be extrapolated to CABG given the very different therapeutic mechanisms of action of these interventions. What was once a simple static plumbing problem for coronary surgeons has become remarkably more complex with our evolving understanding of the dynamic interplay of coronary physiology and anatomy guiding CABG. We need a lot more knowledge regarding the very basic tenants of CABG on the optimal number and location of coronary grafts to maximize the effectiveness of surgical revascularization. Invasive physiological assessment of coronary lesions in its present form is unlikely to reach this goal. In the Posterior left pericardiotomy for the prevention of AtriaL fibrillation After Cardiac Surgery (PALACS) trial, posterior left pericardiotomy significantly reduced the incidence of in-hospital post-operative atrial fibrillation (POAF) and pericardial effusion compared with no intervention. In a Rapid Communication article entitled ‘Posterior left pericardiotomy in cardiac surgery and outcomes: PALACS-EF trial extended follow-up’, Mario Gaudino from Weill Cornell Medicine in New York, NY, USA, and colleagues evaluate the long-term clinical effects of posterior left pericardiotomy in cardiac surgery patients.28 In the initial trial, posterior left pericardiotomy was found to reduce the incidence of POAF by 56% compared with no intervention (17% [37/212] vs. 32% [66/208], P < .001). The purpose of the present study (PALACS-Extended Follow-Up [PALACS-EF]) was to evaluate the long-term clinical outcomes associated with posterior left pericardiotomy. The study was a prospective, extended follow-up of all 420 patients initially enrolled in PALACS. The primary outcome of PALACS-extended follow-up was time to first occurrence of the composite of all-cause mortality or hospital readmission for cardiovascular causes. Key secondary outcome was the time to first occurrence of the composite of all-cause mortality and all-cause hospital readmission, with other secondary outcomes including myocardial infarction, cerebrovascular accidents, heart failure, and new arrhythmias with onset after 30 days. Over a median of 5.2 years, there was no significant difference between groups in the primary or key secondary outcomes (P = .7 and P = .74, respectively). Posterior left pericardiotomy reduced the risk of the primary and key secondary outcomes in the first 3 months following surgery (P = .04 and P = .01, respectively), but this was not sustained over the follow-up. The authors conclude that posterior left pericardiotomy is associated with an early reduction of events, but this effect is not sustained throughout the duration of the study. PALACS-EF demonstrates the utility of posterior left pericardiotomy in improving outcomes in the months following cardiac surgery; however, more research is necessary to better elucidate the entirety of the clinical and financial effects. The editors hope that this issue of the European Heart Journal will be of interest to its readers. Dr. Crea reports speaker fees from Abbott, Amgen, Astra Zeneca, BMS, Chiesi, Daiichi Sankyo, Menarini outside the submitted work. With thanks to Lindsay Washington, Johanna Huggler, Amelia Meier- Batschelet, and Martin Meyer for help with compilation of this article.
No takes yet. Share an insight, caveat, or question.
Filippo Crea (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: